Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

665
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
665
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

511
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
511
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

598
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
598
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

153
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
153

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of intraocular pressure control on visual field progression in the HORIZON trial.

Ophthalmology. Glaucoma·2026
Same author

Patient and staff experiences of a community-based diagnostic clinic for chronic eye conditions: Qualitative analysis.

Eye (London, England)·2026
Same author

Reply to Comment on: Assessing the Fragility of Statistically Significant Outcomes in Randomized Controlled Trials of Minimally Invasive Glaucoma Surgery (MIGS).

American journal of ophthalmology·2026
Same author

Design and Baseline Characteristics of Participants in the Clarifying the Optimal Application of Selective Laser Trabeculoplasty (SLT) Therapy (COAST) Trial 1.

Journal of glaucoma·2026
Same author

Validating and updating the OHTS-EGPS model predicting 5-year glaucoma risk among patients with ocular hypertension using electronic medical records: a cohort study.

Health technology assessment (Winchester, England)·2026
Same author

Optimizing Filtration Surgery Procedures in African-Derived Populations: Trabeculectomy and Preserflo.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Tubing the trabeculectomy: a novel filtration technique.

Eye (London, England)·2026
Same journal

Retinal non-perfusion progression in severe non-proliferative and proliferative diabetic retinopathy over time: INSPIRED study report 2.

Eye (London, England)·2026
Same journal

Macular serpiginous choroiditis versus macular serpiginous-like choroiditis: clinical features, outcomes and prognosis.

Eye (London, England)·2026
Same journal

Association of baseline brain care score with the incidence of age-related eye diseases.

Eye (London, England)·2026
Same journal

A comparative analysis of carbon dioxide versus nitrous oxide as the pressurised gas driving a retinal cryotherapy unit.

Eye (London, England)·2026
Same journal

Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease.

Eye (London, England)·2026
See all related articles

Related Experiment Video

Updated: Aug 6, 2025

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
08:55

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

3.1K

Clinical risk stratification in glaucoma.

Ali Poostchi1, Alan Kastner1,2, Evgenia Konstantakopoulou1,3,4,5

  • 1Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.

Eye (London, England)
|March 15, 2023
PubMed
Summary
This summary is machine-generated.

Developing effective glaucoma risk stratification models is crucial for preventing sight loss in the UK. These models need to incorporate patient-specific factors beyond simple disease staging for optimal care.

More Related Videos

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.4K

Related Experiment Videos

Last Updated: Aug 6, 2025

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
08:55

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

3.1K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.4K

Area of Science:

  • Ophthalmology
  • Public Health

Background:

  • Glaucoma is a leading cause of preventable blindness in the UK.
  • Timely glaucoma care presents significant challenges.
  • A recent investigation recommended risk stratification model validation to protect patient quality of life.

Purpose of the Study:

  • Critically appraise current glaucoma risk stratification evidence.
  • Discuss the application of these models in UK glaucoma care.
  • Highlight the need for refined, individualized risk stratification.

Main Methods:

  • Review of existing literature on glaucoma risk stratification.
  • Analysis of factors for refined models: visual impairment, disability, comorbidities, progression rate, visual needs, driving status.
  • Discussion of clinical refinement and validation requirements.

Main Results:

  • No nationally agreed evidence-based risk stratification model currently exists in the UK.
  • Existing models often use simple disease staging (e.g., visual field mean deviation).
  • The COVID-19 pandemic accelerated the development and evaluation of risk stratification models.

Conclusions:

  • Individualized risk stratification models incorporating multiple factors are needed.
  • Clinical refinement and validation are essential for implementing these models.
  • Further research is required to justify and validate their utility in routine practice.